Predicting outcome in ex-premature infants supported with extracorporeal membrance oxygenation for acute hypoxic respiratory failure

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 89, Issue 5, 2004, Pages

  Brown, K L ^a   Walker, S ^c   Grant, D J ^d   Tanner, K ^e   Ridout, D A ^b   Snekerdemian, L S ^a   Smith, J H ^e   Davis, C ^c   Firmin, R K ^d   Goldman, A P ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d GLENFIELD HOSPITAL   (United Kingdom)

^e FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN;

ACUTE RESPIRATORY FAILURE; AGE; BIRTH; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DEATH; DISABILITY; EXTRACORPOREAL OXYGENATION; FOLLOW UP; GENERAL PRACTITIONER; GESTATIONAL AGE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MORBIDITY; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NEWBORN HYPOXIA; NEWBORN INTENSIVE CARE; OUTCOMES RESEARCH; PATIENT REFERRAL; PEDIATRICIAN; PREDICTION; PREMATURITY; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; UNITED KINGDOM;

ACUTE DISEASE; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; PROGNOSIS; RESPIRATORY INSUFFICIENCY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEASONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4444270986     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2003.033308     Document Type: Review

References (22)

1. Extracorporeal life support organisation. ECLS Registry Report. International Summary, January 2001.
2. UK Collaborative ECMO Group. UK collaborative randomised trial of neonatal extra corporeal membrane oxygenation. Lancet 1996;348:75-82.
3. Hui TT, Danielson PD, Anderson KD, et al. The impact of changing neonatal respiratory management on extracorporeal membrane oxygenation utilisation. J Pediatr Surg 2002;37:703-5.
4. Lorenz JM. The outcome of extreme prematurity. Semin Perinatol 2001;25:348-59.
5. Hack M, Fanaroff AA. Outcomes of children with extremely low birthweight and gestational age in the 1990s. Semin Neonatol 2000;5:89-106.
6. Sauve RS, Christianson HE, Lieske DJ. As mortality rates decrease in extremely low birth weight infants. Pediatric Academic Societies and the American Association of Pediatrics 2000: Joint Meeting Poster V41.
7. University of Leicester. Trent Neonatal Survey Annual Report. University of Leicester, 2001.
8. Cunningham CK, McMillan JA, Gross SJ. Rehospitalisation for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991;88:527-32.
9. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants. Arch Dis Child 2000;83:122-7.
10. Wang EL, Law BL, Stephens D, et al. PICNIC prospective study of risk factors and outcomes in patients hospitalised with RSV lower respiratory tract infection. J Pediatr 1995;126:213-17.
11. Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of paluvizimab in the prevention of respiratory syncytial virus infection in infants at high risk of infection. West Midlands Health Technology Assessment Group, 2001.
12. Clark SJ, Beresford MW, Subhedar NV, et al. Respiratory syncytial virus infection in high-risk infants and the potential impact of prophylaxis in the UK. Arch Dis Child 2000;83:313-16.
13. Greenough A. Respiratory syncytial virus infection: clinical features, management and prophylaxis. Curr Opin Pulm Med 2002;8:214-17.
14. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of RSV infections: indications for the use of Paluvizimab and update on the use of RSV-IG. Pediatrics 1998;102:1211-16.
15. Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with paluvizimab, a humanized RSV monoclonal antibody: a consensus opinion. Pediatr Infect Dis J 1999;18:223-31.
16. Bennett CC, Johnson A, Field DJ, et al. UK collaborative randomised trial of neonatal ECMO: follow up at 4 years. Lancet 2001;357:1094-5.
17. Bont L, van Aalderen W, Kimpen J. Long term consequences of RSV bronchiolitis. Paediatr Respir Rev 2000;1:221-7.
18. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9.
19. Majnemer A, Riley P, Shevell M, et al. Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors. Dev Med Child Neurol 2000;42:53-60.
20. Hibbs A, Evans JR, Gerdes M, et al. Outcome of infants with bronchopulmonary dysplasia who receive ECMO therapy. J Pediatr Surg 2001;36:1479-84.
21. Pranikoff T, Hirchl R, Steimle CN, et al. Mortality is directly related to duration of ventilation before initiation of ECMO. Crit Care Med 1997;25:28-32.
22. Bulas DI, Taylor GA, O'Donnell RM, et al. Intracranial abnormalities in infants treated with ECMO: update on sonographic and CT findings. Am J Neuroradiol 1996;17:287-94.